Synonyms: Arlansa® | SCH 900518 | SCH-900518 | SCH900518
narlaprevir is an approved drug (Russia (2016))
Compound class:
Synthetic organic
Comment: Narlaprevir (SCH90051) is an oral HCV NS3 serine protease inhibitor [1,3]. It is structurally related to boceprevir. Narlaprevir forms a reversible covalent bond with the protease's active-site serine. It has also been reported to inhibit SARS-CoV-2 coronavirus main cysteine protease (3CLpro or Mpro) in vitro [2].
|
|
Classification | |
Compound class | Synthetic organic |
Approved drug? | Yes (Russia (2016)) |
IUPAC Name |
narlaprevir |
International Nonproprietary Names | |
INN number | INN |
9227 | narlaprevir |
Synonyms |
Arlansa® | SCH 900518 | SCH-900518 | SCH900518 |
Database Links | |
CAS Registry No. | 865466-24-6 (source: PubChem) |
ChEMBL Ligand | CHEMBL1255891 |
GtoPdb PubChem SID | 441604944 |
PubChem CID | 11857239 |
Search Google for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |
Search Google for chemicals with the same backbone | RICZEKWVNZFTNZ |
Search PubMed clinical trials | narlaprevir |
Search PubMed titles | narlaprevir |
Search PubMed titles/abstracts | narlaprevir |
UniChem Compound Search for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | RICZEKWVNZFTNZ-LFGITCQGSA-N |